NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
TNGX
Tango Therapeutics, Inc.
There isn't enough reported data to score TNGX yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TNGX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
TNGX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | โ |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
TNGX PE Valuation
TNGX has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TNGX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect TNGX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TNGX on earnings quality, reporting a profit while its opponent remains loss making.
TNGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | -$0.46 |
| Q2 2026 | -$0.85 | +$0.46 |
| Q1 2026 | -$0.83 | +$0.37 |
| Q4 2025 | -$0.87 | +$0.32 |
| Q3 2025 | -$0.91 | +$0.25 |
| Q2 2025 | -$1.31 | -$0.19 |
| Q1 2025 | -$1.20 | -$0.09 |
| Q4 2024 | -$1.19 | -$0.11 |
TNGX lost $1.37 per share over the past year, a bigger loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over TNGX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
TNGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $53.8M | +364% |
| Q2 2025 | $3.2M | -84% |
| Q1 2025 | $5.4M | -17% |
| Q4 2024 | $4.1M | -24% |
| Q3 2024 | $11.6M | +8.2% |
| Q2 2024 | $19.9M | +36% |
| Q1 2024 | $6.5M | +12% |
| Q4 2023 | $5.4M | -15% |
TNGX's revenue has slid since its 2025 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | 26% | +309 points |
| Q2 2025 | -1288% | -1139 points |
| Q1 2025 | -789% | -136 points |
| Q4 2024 | -994% | -349 points |
| Q3 2024 | -283% | -45 points |
| Q2 2024 | -149% | +11 points |
| Q1 2024 | -653% | -128 points |
| Q4 2023 | -645% | -168 points |
TNGX's operating margin was 26% last quarter, up 309 points from the same quarter a year ago, near the top of its range since 2020.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over TNGX on cash generation, producing positive trailing cash flow while its opponent burns cash.
TNGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.2M | -$6.1M |
| Q2 2026 | -$38.9M | -$1.7M |
| Q1 2026 | -$44.4M | -$2.6M |
| Q4 2025 | -$29.9M | +$6.8M |
| Q3 2025 | -$31.1M | +$2.4M |
| Q2 2025 | -$37.1M | -$13.2M |
| Q1 2025 | -$41.7M | -$3.7M |
| Q4 2024 | -$36.8M | -$9.1M |
TNGX has burned cash in almost every quarter: โ$150M over the past year, against โ$147M the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
TNGX Net Leverage
TNGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TNGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.8 | Neutral |
| Stochastic | 27.6 | Neutral |
TNGX's weekly RSI is 54 (neutral) and its Stochastic is 28 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TNGX PE vs Healthcare Sector
TNGX has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
TNGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.3 | 6.7% above |
| 20 week MA | $24.9 | 0% below |
| 50 week MA | $20.5 | 21% above |
| 100 week MA | $12.6 | 97% above |
| 200 week MA | $9.89 | 151% above |
TNGX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
TNGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $11.3 | +9.9% |
| 2021 | $11.3 | $10.9 | -2.8% |
| 2022 | $10.9 | $7.83 | -28% |
| 2023 | $7.83 | $9.90 | +26% |
| 2024 | $9.90 | $3.12 | -68% |
| 2025 | $3.12 | $8.67 | +178% |
| 2026 YTD | $8.67 | $24.9 | +187% |
TNGX has the edge over NVO on returns for 2026, with the stronger performance.